Aquestive Therapeutics Reports Positive Topline Results From Final Two Arms Of EPIPHAST Trial

Aquestive Therapeutics, Inc. (AQST), a pharmaceutical company, announced Monday positive topline results from the final two arms of Part 3 of the EPIPHAST study for its AQST-109 epinephrine oral film.

AQST-109 is a polymer matrix-based epinephrine prodrug administered as a sublingual film that is applied under the tongue for the rapid delivery of epinephrine.

EPIPHAST was a randomized, open-label, three-part adaptive design, crossover study comparing the pharmacokinetics and pharmacodynamics of epinephrine delivered through the company's AQST-109 oral film compared to intramuscular injection of epinephrine.

The study was being conducted pursuant to clearance from Health Canada.

According to the company, the purpose of Part 3 was to continue to study the administration of the film under a variety of conditions to further characterize its pharmacokinetics, pharmacodynamics, and safety.

The final two arms were designed to assess the impact of administering the film sublingually two minutes after consuming a peanut butter sandwich, and swallowing the film whole immediately with water.

Dan Barber, Chief Executive Officer of Aquestive, said, "We are thrilled to conclude and share the data from Part 3 of the EPIPHAST study further demonstrating AQST-109's strong and differentiated pharmacokinetic performance under a variety of conditions which now includes dosing the sublingual film after eating a peanut butter sandwich and swallowing the film whole immediately with water. It is very promising that AQST-109 continues to perform well in challenging and less than ideal circumstances, further validating performance and real-world functionality."

Aquestive said EPIPHAST II, a crossover study, is now underway, comparing AQST-109 to epi 0.3mg IM injection (repeat dose) and AQST-109 to EpiPen 0.3mg (single dose).

This data, along with the data from the complete EPIPHAST study, will be the basis for the End-of-Phase 2 meeting with the FDA that the company plans to request in the fourth quarter 2022.

For More Such Health News, visit rttnews.com

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Integrated energy company Chevron reported Friday that profit for the fourth quarter increased 25 percent from last year, reflecting 17 percent revenue growth amid higher realizations and higher margins on refined product sales. Adjusted earnings per share missed analysts' estimates, while quarterly revenues topped it. Reno, Nevada-based ZLINE Kitchen and Bath has expanded its recall of gas ranges citing serious risk of injury or death from carbon monoxide poisoning, the U.S. Consumer Product Safety Commission announced. The recall now includes about 30,000 units of ZLINE gas ranges, including about 28,000 units... The Food and Drug Administration's independent advisory committee unanimously recommended replacing the current original COVID vaccines used in the U.S. for primary shots with new bivalent omicron shots authorized as boosters, reports said. The committee also considered the proposal for annual COVID vaccination, however, didn't vote on it.
Follow RTT